Neo Ivy Capital Management Acquires New Holdings in Amicus Therapeutics, Inc. $FOLD

Neo Ivy Capital Management bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 49,264 shares of the biopharmaceutical company’s stock, valued at approximately $388,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Legato Capital Management LLC boosted its holdings in Amicus Therapeutics by 37.3% in the third quarter. Legato Capital Management LLC now owns 40,211 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,934 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Amicus Therapeutics by 231.3% in the third quarter. Victory Capital Management Inc. now owns 342,848 shares of the biopharmaceutical company’s stock worth $2,702,000 after buying an additional 239,367 shares during the last quarter. William Blair Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 7.6% during the 3rd quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock worth $124,104,000 after acquiring an additional 1,107,083 shares in the last quarter. R Squared Ltd increased its holdings in shares of Amicus Therapeutics by 82.0% during the 3rd quarter. R Squared Ltd now owns 25,824 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 11,636 shares during the last quarter. Finally, DNB Asset Management AS raised its stake in shares of Amicus Therapeutics by 17.6% in the 3rd quarter. DNB Asset Management AS now owns 46,161 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 6,920 shares in the last quarter.

Amicus Therapeutics Trading Up 0.1%

Shares of Amicus Therapeutics stock opened at $14.34 on Monday. The company’s fifty day simple moving average is $14.31 and its 200-day simple moving average is $10.96. The company has a market cap of $4.50 billion, a price-to-earnings ratio of -179.25 and a beta of 0.43. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The company had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. During the same quarter in the previous year, the company earned $0.09 earnings per share. Amicus Therapeutics’s revenue for the quarter was up 23.7% compared to the same quarter last year. As a group, sell-side analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Leerink Partners downgraded Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $17.00 to $14.50 in a report on Monday, December 29th. Citigroup reaffirmed a “neutral” rating and set a $14.50 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 26th. Guggenheim downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Finally, Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.39.

Insider Transactions at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $11.00, for a total value of $282,073.00. Following the completion of the sale, the insider owned 271,332 shares in the company, valued at approximately $2,984,652. This trade represents a 8.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. This trade represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 226,711 shares of company stock valued at $2,887,822 in the last ninety days. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.